XTX Markets’s Jazz Pharmaceuticals JAZZ Stock Holding History

XTX Markets’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,442	Closed	-$269K	–	150
2020 Q2	$269K	Buy	+2,442	New	+$270K	0.91%	38

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

XTX Markets's JAZZ Position: Q3 2020 in Review

XTX Markets sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2020, closing a stake of 2,442 shares — an estimated $269K sold.

XTX Markets first reported a position in JAZZ in Q2 2020 and held it in 1 quarter. The position peaked at $269K in Q2 2020. 390 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

XTX Markets reported no remaining Jazz Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
XTX Markets sold 2,442 Jazz Pharmaceuticals shares in Q3 2020, an estimated $269K.
XTX Markets first reported a position in Jazz Pharmaceuticals in Q2 2020 and held it in 1 quarter.
XTX Markets's Jazz Pharmaceuticals position peaked at $269K in Q2 2020.
390 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on XTX Markets's 13F filing for Q3 2020, filed 29 Oct 2020.